Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

ory to, or who have progressed within six months of completing, treatment with first-line platinum chemotherapy (cisplatin or carboplatin), is being conducted at clinical sites in Europe and India.

"Since the initiation of the SPEAR trial in the second quarter of 2007, we have made significant progress in opening approximately 100 clinical sites and in treating patients," said David A. Karlin, M.D., senior vice president, clinical development and regulatory affairs for Poniard. "We anticipate reaching our enrollment target in the first half of 2008, potentially supporting a New Drug Application filing in 2009."

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the FDA in November 2005 for picoplatin for the treatment of SCLC.

In addition to the ongoing SPEAR trial, Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer.

About Small Cell Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, bu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... May 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ... nine months ended March 31, 2012 during the morning of ... a conference call for investors later that day at 3:30 ... nine month periods.  Those interested in participating should call (800) ...
... N.C., May 11, 2012  To broaden their marketing ... strategies and tactics to engage key customer groups ... key opinion leaders. But as they shift to ... viral marketing and other approaches, marketing groups are ...
Cached Medicine Technology:New Report Outlines Use of Innovative Marketing to Engage Customer Groups that are Key to the Pharmaceutical Industry 2
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... NEW YORK April 17, 2014 EcoHealth Alliance, ... public health issues, published a comprehensive review today examining ... and Marburg virus. The review calls for improved global ... such as the recent outbreak of Ebola in West ... in the countries of Guinea and Liberia. According ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today announced ... & Co., a leading global investment bank, as ... evaluating and pursuing alternative,strategies to maximize shareholder value., ... assignment because of its,experience in strategic transactions and ...
... Recent developments regarding,North Carolina,s organ and tissue ... Donation to hire Corder Philips to aid in ... These developments include a grant received from the ... to update their online,registry and increase outreach efforts ...
... Deployed Service Members ... ... the,Military Child Education Coalition,s Supporting the Children of the,National Guard and Reserve ... the Minuteman Emergency,Assistance Fund. The contribution will help support the needs of ...
... VANCOUVER and DEERFIELD, IL, Dec. 11 /PRNewswire-FirstCall/ - ... its co-development partner,Astellas Pharma US, Inc. ("Astellas") today ... of the U.S. Food and Drug,Administration (FDA) has ... of vernakalant hydrochloride, an investigational,new drug for rapid ...
... regions activated by beliefs and human feelings, study shows ... disbelief and uncertainty activate distinct areas of the brain, ... online in the Annals of Neurology . ... was monitored using functional magnetci resonance imaging (fMRI) while ...
... genome-wide association studies have identified a genetic variant ... the risk of aggressive prostate cancer. Research teams ... Forest University School of Medicine, the Karolinska Institute ... made the discovery jointly. , Researchers suspect that ...
Cached Medicine News:Health News:QLT Appoints Goldman, Sachs & Co. as financial advisor in review of strategic options to enhance shareholder value 2Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:TriWest Contributes $25,000 to Washington National Guard Fund and Sponsors Education for Teachers of Military Children 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 3Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 4Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 5Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 6Health News:Personal Convictions May Control Both Behavior and Emotions 2Health News:Study finds gene linked to aggressive prostate cancer 2Health News:Study finds gene linked to aggressive prostate cancer 3
... long, thick-walled cannula which contains a coaxial ... Helical Loop Basket and a Tip Deflecting ... the outer cannula to carry these two ... right atrium. (Requires a Handle for Tip ...
... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... The cost-effective, proven and reliable system. ... for rapid patient treatment, fastest beam-on ... - less than 500 milliseconds, pulse-to-pulse ... beam stability, greatest number of multileaf ...
Medicine Products: